Industry Biotechnology | Founded 2009 | |
 | ||
Key people Brian Leuthner (President & CEO)
R Loch Macdonald (Chief Scientific Officer) Stock price EDGE (NASDAQ) US$ 8.95 +0.20 (+2.29%)10 Mar, 4:00 PM GMT-5 - Disclaimer Headquarters Berkeley Heights, New Jersey, United States | ||
Edge therapeutics inc
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, Edge's lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, Edge's second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.
Contents
- Edge therapeutics inc
- Edge therapeutics video 3 50
- Leadership Team
- Board of Directors
- Clinical Advisors
- References
EG-1962 and EG-1964 both utilize Edge’s proprietary, programmable, biodegradable polymer-based development platform, known as Precisa™. The Precisa platform allows Edge to create therapeutics capable of delivering medicines directly to the site of injury, providing a novel delivery mechanism that enables targeted and sustained drug exposure while potentially avoiding the systemic, dose-limiting side effects often associated with current standards of care.